Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Gastroesophageal Reflux Disease (GERD) Segmentation: Document How Swiss General Practitioners (GPs) Allocate Their GERD Patients to the Three GERD Patient Segments

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: May 29, 2008
Last updated: December 6, 2010
Last verified: December 2010

Document how Swiss GPs allocate their GERD patients to the three GERD patient segments (according to King et al.) and how treated GERD patients are affected by their GERD treatment


Study Type: Observational
Study Design: Time Perspective: Retrospective
Official Title: GERD Segmentation: Document How Swiss GPs Allocate Their GERD Patients to the Three GERD Patient Segments

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • % patients per GERD patient segment [ Time Frame: single visit ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Symptom load [ Time Frame: single visit ] [ Designated as safety issue: No ]
  • Quality of life [ Time Frame: single visit ] [ Designated as safety issue: No ]

Estimated Enrollment: 2912
Study Start Date: February 2008
Study Completion Date: August 2008
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Treated GERD pts
Previously diagnosed GERD patients on treatment in Switzerland


Ages Eligible for Study:   12 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Previously diagnosed GERD patients on treatment for at least 2 weeks; in Switzerland


Inclusion Criteria:

  • Previously diagnosed GERD patients
  • on treatment for at least 2 weeks

Exclusion Criteria:

  • none
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00688675

Research Site
Aarau, Switzerland
Sponsors and Collaborators
  More Information

No publications provided

Responsible Party: Dr med Madeleine Billeter, AstraZeneca AG, Switzerland Identifier: NCT00688675     History of Changes
Other Study ID Numbers: NIS-GCH-NEX-2007/1
Study First Received: May 29, 2008
Last Updated: December 6, 2010
Health Authority: Switzerland: Ethikkommission

Keywords provided by AstraZeneca:

Additional relevant MeSH terms:
Gastroesophageal Reflux
Deglutition Disorders
Digestive System Diseases
Esophageal Diseases
Esophageal Motility Disorders
Gastrointestinal Diseases processed this record on November 20, 2014